ERBB2 and cancer: An example is the signature SBS36/56L, possibly indicating failed BER since SBS36 was previously associated with loss-of-function in MUTYH. In five cancer types, SBS36 was associated with sensitivity to inhibition of EGFR or of ERBB2 via e.g. afatinib or AST-1306 drugs.